313 related articles for article (PubMed ID: 19421040)
1. Intracameral moxifloxacin: in vitro safety on human ocular cells.
Kernt M; Neubauer AS; Liegl RG; Lackerbauer CA; Eibl KH; Alge CS; Ulbig MW; A AK
Cornea; 2009 Jun; 28(5):553-61. PubMed ID: 19421040
[TBL] [Abstract][Full Text] [Related]
2. Intracameral voriconazole: in vitro safety for human ocular cells.
Kernt M; Kampik A
Toxicology; 2009 Apr; 258(2-3):84-93. PubMed ID: 19428927
[TBL] [Abstract][Full Text] [Related]
3. In vitro safety of intravitreal moxifloxacin for endophthalmitis treatment.
Kernt M; Neubauer AS; Ulbig MW; Kampik A; Welge-Lüssen U
J Cataract Refract Surg; 2008 Mar; 34(3):480-8. PubMed ID: 18299076
[TBL] [Abstract][Full Text] [Related]
4. [Intracameral moxifloxacin: a safe option for endophthalmitis prophylaxis? In vitro safety profile for intraocular application].
Kernt M; Hirneiss C; Neubauer AS; Liegl RG; Eibl KH; Wolf A; de Kaspar H; Ulbig MW; Kampik A
Ophthalmologe; 2010 Aug; 107(8):720-7. PubMed ID: 19756636
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal voriconazole: in vitro safety-profile for fungal endophthalmitis.
Kernt M; Neubauer AS; De Kaspar HM; Kampik A
Retina; 2009 Mar; 29(3):362-70. PubMed ID: 18997637
[TBL] [Abstract][Full Text] [Related]
6. Intraocular caspofungin: in vitro safety profile for human ocular cells.
Kernt M; Kampik A
Mycoses; 2011 Jul; 54(4):e110-21. PubMed ID: 20202116
[TBL] [Abstract][Full Text] [Related]
7. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model.
Kowalski RP; Romanowski EG; Mah FS; Yates KA; Gordon YJ
Am J Ophthalmol; 2005 Sep; 140(3):497-504. PubMed ID: 16083841
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery.
Lane SS; Osher RH; Masket S; Belani S
J Cataract Refract Surg; 2008 Sep; 34(9):1451-9. PubMed ID: 18721703
[TBL] [Abstract][Full Text] [Related]
9. Safety of moxifloxacin as shown in animal and in vitro studies.
McGee DH; Holt WF; Kastner PR; Rice RL
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S46-54. PubMed ID: 16257310
[TBL] [Abstract][Full Text] [Related]
10. Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration.
Hariprasad SM; Mieler WE; Shah GK; Blinder KJ; Apte RS; Holekamp NM; Thomas MA; Chi J; Prince RA
Trans Am Ophthalmol Soc; 2004; 102():149-55; discussion 155-7. PubMed ID: 15747753
[TBL] [Abstract][Full Text] [Related]
11. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients.
Espiritu CR; Caparas VL; Bolinao JG
J Cataract Refract Surg; 2007 Jan; 33(1):63-8. PubMed ID: 17189795
[TBL] [Abstract][Full Text] [Related]
12. Ocular pharmacokinetics, safety and efficacy of intracameral moxifloxacin 0.5% solution in a rabbit model.
Asena L; Akova YA; Goktaş MT; Bozkurt A; Yaşar U; Karabay G; Demiralay E
Curr Eye Res; 2013 Apr; 38(4):472-9. PubMed ID: 23373761
[TBL] [Abstract][Full Text] [Related]
13. Aqueous humor and plasma concentrations of ciprofloxacin and moxifloxacin following topical ocular administration in ophthalmologically normal horses.
Clode AB; Davis JL; Salmon J; LaFevers H; Gilger BC
Am J Vet Res; 2010 May; 71(5):564-9. PubMed ID: 20433383
[TBL] [Abstract][Full Text] [Related]
14. Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro.
Kim SY; Lim JA; Choi JS; Choi EC; Joo CK
Cornea; 2007 Jul; 26(6):720-5. PubMed ID: 17592324
[TBL] [Abstract][Full Text] [Related]
15. The effects of 5-fluorouracil on ocular tissues in vitro and in vivo after controlled release from a multifunctional implant.
Huhtala A; Rönkkö S; Teräsvirta M; Puustjärvi T; Sihvola R; Vehanen K; Laukkanen A; Anttila J; Urtti A; Pohjonen T; Uusitalo H
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2216-23. PubMed ID: 19136700
[TBL] [Abstract][Full Text] [Related]
16. [Multikinase inhibitors as a new approach in neovascular age-related macular degeneration (AMD) treatment: in vitro safety evaluations of axitinib, pazopanib and sorafenib for intraocular use].
Thiele S; Liegl RG; König S; Siedlecki J; Langer J; Eibl K; Haritoglou C; Kampik A; Kernt M
Klin Monbl Augenheilkd; 2013 Mar; 230(3):247-54. PubMed ID: 23508753
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferative and cytotoxic properties of moxifloxacin on rat retinal ganglion cells.
Sobolewska B; Hofmann J; Spitzer MS; Bartz-Schmidt KU; Szurman P; Yoeruek E
Curr Eye Res; 2013 Jun; 38(6):662-9. PubMed ID: 23654355
[TBL] [Abstract][Full Text] [Related]
18. Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery.
Arbisser LB
J Cataract Refract Surg; 2008 Jul; 34(7):1114-20. PubMed ID: 18571078
[TBL] [Abstract][Full Text] [Related]
19. Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device.
Hariprasad SM; Shah GK; Chi J; Prince RA
J Cataract Refract Surg; 2005 Nov; 31(11):2142-6. PubMed ID: 16412929
[TBL] [Abstract][Full Text] [Related]
20. Effects of intravitreal moxifloxacin and dexamethasone in experimental Staphylococcus aureus endophthalmitis.
Ermis SS; Cetinkaya Z; Kiyici H; Inan UU; Ozturk F
Curr Eye Res; 2007 Apr; 32(4):337-44. PubMed ID: 17453955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
